Insys Therapeutics treatment of Lennox-Gastaut syndrome granted orphan status Insys Therapeutics' cannabidiol was granted FDA orphan designation as a treatment of Lennox-Gastaut syndrome, according to a post to the regulator's website. Reference Link
Insys Therapeutics longer term outlook stable, says RBC Capital After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .